Breast Cancer Clinical Trials near Houston, TX


185 studies for Breast Cancer are recruiting at 323 sites within 50 miles of Houston, Texas, according to ClinicalTrials.gov data processed .
Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Houston.
Recruiting now
Breast Cancer studies enrolling near Houston
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
- Phase 3
- Ages 18 to 60 years
- Sex: Female
Nearest sites: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (Houston, TX); Ben Taub General Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 18 sites within 50 mi
- Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (Houston, TX); Ben Taub General Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 15 sites within 50 mi
- De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
- Phase 3
- Ages 50 to 70 years
- Sex: All
Nearest sites: Houston Methodist Hospital (Houston, TX); Houston Methodist West Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 14 sites within 50 mi
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT06876714
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Houston Methodist Hospital (Houston, TX); Houston Methodist West Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 14 sites within 50 mi
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
NCT07391774
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Houston Methodist Hospital (Houston, TX); Houston Methodist West Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 8 sites within 50 mi
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (Houston, TX); Ben Taub General Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 7 sites within 50 mi
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446
- Phase 2
- Ages 18 years and older
- Sex: All
Nearest sites: MD Anderson West Houston (Houston, TX); The University of Texas M. D. Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 6 sites within 50 mi
- QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116
- Observational
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (Houston, TX); Ben Taub General Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 6 sites within 50 mi
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: MD Anderson West Houston (Houston, TX); The University of Texas M. D. Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 6 sites within 50 mi
- Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
NCT00477100
- Observational
- Ages 18 years and older
- Sex: All
Nearest sites: M D Anderson Cancer Center (Houston, TX); MD Anderson in Katy (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
- Observational
- Ages 18 years and older
- Sex: All
Nearest sites: Texas Oncology - Memorial City (Houston, TX); Texas Oncology Willowbrook (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: The University of Texas - M.D. Anderson Cancer Center (Houston, TX); The University of Texas, MD Anderson Cancer Center - West Houston (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT04169542
- Observational
- Ages 18 years and older
- Sex: Female
Nearest sites: M D Anderson Cancer Center (Houston, TX); MD Anderson in Sugar Land (Sugar Land, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 4 sites within 50 mi
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Oncology Consultants P.A. (Houston, TX); Tranquility Research (Webster, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 4 sites within 50 mi
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: Oncology Consultants, PA (Houston, TX); Oncology Consultants, PA. (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor College of Medicine (Houston, TX); Harris Health System - Smith Clinic (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- Patient Priorities for Survivorship Care in Older Breast Cancer Survivors
NCT06478589
- Phase 2
- Ages 65 to 100 years
- Sex: Female
Nearest sites: Memorial Hermann Cancer Center (Houston, TX); UT Physicians Family Medicine Bayshore (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT06764940
- Phase 2
- Ages 18 years and older
- Sex: All
Nearest sites: MD Anderson Cancer Center (Houston, TX); Tranquil Clinical Research (Webster, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Kelsey-Seybold Clinic ( Site 0042) (Houston, TX); Kelsey-Seybold Clinic ( Site 0088) (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Oncology Consultants PA (Houston, TX); Oncology Consultants PA (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT03796559
- Interventional
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor Medicine (Houston, TX); MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449
- Phase 1/2
- Ages 18 years and older
- Sex: All
Nearest sites: The University of Texas MD Anderson Cancer Center (Houston, TX); The University of Texas, MD Anderson Cancer Center - West Houston (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860
- Phase 2
- Ages 18 years and older
- Sex: All
Nearest sites: Harris Health System - Smith Clinic (Houston, TX); O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: The University of Texas MD Anderson Cancer Center (Houston, TX); The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916
- Phase 3
- Ages 18 to 100 years
- Sex: All
Nearest sites: Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center (Houston, TX); Texas Oncology - Gulf Coast (Sugar Land, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377
- Phase 2
- Ages Any age
- Sex: All
Nearest sites: Lyndon Baines Johnson General Hospital (Houston, TX); UT MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT05660083
- Phase 2
- Ages 18 years and older
- Sex: All
Nearest sites: Houston Methodist Neal Cancer Center (Houston, TX); The University of Texas MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (Houston, TX); Ben Taub General Hospital (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: Oncology Consultants, P.A. (Houston, TX); University of Texas M.D. Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
NCT06085833
- Interventional
- Ages 18 years and older
- Sex: All
Nearest sites: Baylor College of Medicine (Houston, TX); MD Anderson Cancer Clinic - Mays Clinic (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: The University of Texas MD Anderson Cancer Center (Houston, TX); University of Texas Health Science Center at Houston (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: NEXT Houston (Houston, TX); University of Texas MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357
- Phase 1/2
- Ages 18 years and older
- Sex: All
Nearest sites: The Methodist Hospital Research Institute (Houston, TX); The University of Texas MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Research Site (Houston, TX); Research Site (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Oncology Consultants P.A. ( Site 0107) (Houston, TX); Texas Oncology - Gulf Coast ( Site 8009) (Webster, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Kelsey-Seybold Clinic ( Site 0040) (Houston, TX); Kelsey-Seybold Clinic - North Houston Campus ( Site 0096) (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Houston Methodist Hospital Cancer Center (Houston, TX); The University of Texas M.D. Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559
- Phase 2
- Ages 18 years and older
- Sex: All
Nearest sites: Houston Methodist Cancer Center (Houston, TX); The University of Texas M.D. Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Oncology Consultants P.A. ( Site 0061) (Houston, TX); Texas Oncology - Gulf Coast ( Site 8006) (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098
- Phase 2
- Ages 18 years and older
- Sex: Female
Nearest sites: Oncology Consultants P.A. (Houston, TX); University of Texas MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917
- Phase 1/2
- Ages 18 years and older
- Sex: All
Nearest sites: Lumi Research (Houston, TX); University of Texas-MD Anderson (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: MD Anderson (Houston, TX); NEXT Texas LLC - Houston (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322
- Phase 1
- Ages 18 years and older
- Sex: All
Nearest sites: NEXT Houston (Houston, TX); The University of Texas MD Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT00991094
- Observational
- Ages 18 years and older
- Sex: All
Nearest site: M D Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
NCT02918474
- Interventional
- Ages 18 years and older
- Sex: Female
Nearest site: M D Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT02945579
- Interventional
- Ages 30 years and older
- Sex: Female
Nearest site: M D Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
NCT03408353
- Observational
- Ages 25 to 80 years
- Sex: Female
- Accepts healthy volunteers
Nearest site: M D Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- The PREDICT Registry:
NCT03448926
- Observational
- Ages 30 to 85 years
- Sex: Female
Nearest site: Baylor College of Medicine (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774
- Observational
- Ages Any age
- Sex: All
Nearest site: Massive Bio SYNERGY-AI site (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT03604315
- Phase 1
- Ages 18 years and older
- Sex: Female
Nearest site: M D Anderson Cancer Center (Houston, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
FAQ
Common questions
What is a clinical trial?
Is there compensation for joining a Breast Cancer clinical trial?
How do I check if I'm eligible?
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.